PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages.
We assessed the anti-human immunodeficiency virus (anti-HIV) activity in vitro of new platelet-activating factor (PAF) receptor antagonists, as PAF and viral replication are thought to be involved in HIV neuropathogenesis. We found that PMS-601 inhibited proinflammatory cytokine synthesis and HIV replication in macrophages and potentiated the antiretroviral activity of zidovudine. These results suggest that PMS-601 is of potential value as an adjuvant treatment for HIV infection.
Martin
M
M
CEA, Service de Neurovirologie, DSV/DRM, CRSSA, EPHE, Institut Paris-Sud sur les Cytokines, Fontenay aux Roses, France.
Serradji
N
N
Dereuddre-Bosquet
N
N
Le Pavec
G
G
Fichet
G
G
Lamouri
A
A
Heymans
F
F
Godfroid
J J
JJ
Clayette
P
P
Dormont
D
D
D019380:Anti-HIV Agents / Q000494:pharmacology*; D004357:Drug Synergism; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000821:virology*; D010879:Piperazines / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology
D019380:Anti-HIV Agents; C410215:PMS 601; D010879:Piperazines; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D015215:Zidovudine